Several bacterial species have inherent ability to colonize solid tumors in vivo. However, their natural anti-tumor activity can be enhanced by genetic engineering that enables these bacteria express or transfer therapeutic molecules into target cells. In this review, we summarize latest research on cancer therapy using genetically modified bacteria with particular emphasis on blocking tumor angiogenesis. Despite recent progress, only a few recent studies on bacterial tumor therapy have focused on anti-angiogenesis. Bacteria-mediated anti-angiogenesis therapy for cancer, however, is an attractive approach given that solid tumors are often characterized by increased vascularization. Here, we discuss four different approaches for using modified bacteria as anti-cancer therapeutics-bactofection, DNA vaccination, alternative gene therapy and transkingdom RNA interference-with a specific focus on angiogenesis suppression. Critical areas and future directions for this field are also outlined.
INTRODUCTION
The first modern attempts at using bacteria for therapeutic purposes were made more than 40 years ago. At this time, it was discovered that bacteria could predominantly replicate in solid tumors. 1 However, the first indications of this phenomenon date back to 19th century. These findings remained largely unexplored until the turn of 20th century, when oncolytic bacteria capable of lysing host cells were first studied by various research groups. [2] [3] [4] One of the main reasons for the lack of efficacy of radiotherapy and chemotherapy for many solid tumors is presence of hypoxic areas that are resistant to these interventions. This apparent limitation, however, can be exploited for enhancing tumor-targeting, such as the application of obligate or facultative anaerobic bacteria. Several strains of Clostridia, Bifidobacteria and Salmonellae are able to selectively colonize the hypoxic areas of tumors and destroy the tumor cells, and thereby provide a more selective tumor-targeted therapy. 5 Two crucial shortcomings of conventional cancer treatments can, therefore, be potentially overcome by using tumor-targeting bacteria: off-target tissue toxicity seen in systemic therapies; and hypoxia-related resistance to conventional therapies.
Until recently, nearly all tumor-targeting bacterial strains showed exclusive accumulation in the large central necrotic area of the tumor. Necrotic areas are separated from viable tumor cells by a barrier of host leukocytes thereby leaving the viable areas of the tumor unaffected by the bacteria. Recent studies have shown, however, that this issue can be overcome by the depletion of neutrophils from the host, which results in bacterial colonization of viable and necrotic tumor tissue, and complete eradication of tumors. 6 The historical development and molecular mechanisms of anaerobic bacteria as tumor targeting vectors are reviewed in detail elsewhere. 5, [7] [8] [9] The concept of bacterial oncolytic therapy has been verified in numerous experimental, as well as clinical studies. Recently, a tumortargeting auxotrophic strain of Salmonella typhimurium has been shown to completely eradicate primary tumors, as well as cancer metastases in various mouse models. 10, 11 However, the most frequently used anti-cancer approach using bacteria is enzyme-prodrug therapy where systemically administered bacteria are used to deliver a gene/enzyme able to convert systemically administered prodrug into its active compound specifically in tumor tissue. [12] [13] [14] The utilization of bacterial systems for therapeutic purposes is further enhanced by genetic modifications, which make them a very promising tool for targeted delivery of genes and their products. Specific advantages of using bacteria for anti-cancer gene therapy include the natural oncolytic potential of some strains/species, direct targeting of tumor tissue and the ease of positive regulation/eradication. Moreover, the anti-cancer effect of tumor-targeting bacteria can also be achieved after oral administration, which may circumvent the use of the intravenous route of delivery and its associated adverse events. 15 Nowadays, therapeutics developed on the basis of bacterial carrier vectors are undergoing a phase where several concepts are being advanced into clinical trials as a sign of maturation of the field. Several bacterial therapeutic approaches are showing promising results in clinical phase I and II trials. Listeria is being actively developed as therapeutic agents using the anticancer-vaccination approach. In a Phase I study done in patients with cervical cancer, safety of a live attenuated Listeria monocytogenes that secretes the HPV16 E7 antigen in a fusion construct to the Listeria protein Listeriolysin O has been demonstrated. 16 Phase II studies are ongoing. Recently, Escherichia coli targeting b-catenin has received clearance from US Food and Drug Administration to initiate clinical trials for treating patients with familial adenomatous polyposis. 17 The concept of using Mycobacterium for cancer treatment goes back to the 19th century. Today, bacillus Calmette-Guerin vaccine is an approved treatment for human bladder cancer that is superior to intravesical chemotherapy and is commonly used as the first-line adjuvant treatment. 18 The therapy is known to work through a mechanism of action that includes angiogenesis inhibition, providing a supportive rationale for cancer therapy on the basis of suppression of angiogenesis using bacteria.
Despite recent progress, only a few recent studies on bacterial tumor therapy have specifically focused on anti-angiogenic therapy. Although effects on the vasculature were observed in most of these studies, these changes seemed to be a consequence mainly of bacteria-mediated therapy. Bacteria-mediated anti-angiogenesis tumor therapy, however, is a reasonable approach given that solid tumors are often characterized by increased vascularization. In this review, we summarize latest research on cancer therapy using genetically modified bacteria with particular emphasis on the potential of blocking tumor angiogenesis, and pinpoint critical areas and future directions for this field.
BACTERIA AFFECTING ANGIOGENESIS
Pronounced angiogenesis is one of the hallmarks of solid tumors. Therefore, to search for more efficient anti-cancer drugs, efforts are being made to block tumor angiogenesis. Despite notable successes achieved in studies using oncolytic bacteria for cancer treatment, bacteriolytic therapy in and of itself is often insufficient for complete eradication of experimental tumors. 19 The idea of using combined therapy with bacteria and angiogenesis inhibition has therefore been suggested. 20 Bacterial infection is often accompanied by increased oxygen tension and the generation of immune responses in neighborhood of tumor, which is well-perfused and oxygenated. Jia et al. 21 successfully addressed this issue by the application of an attenuated, auxotrophic Salmonella strain (unable to induce septic shock) in combination with endostatin (an endogenous angiogenesis inhibitor) in a murine model of malignant melanoma. Separate therapy using bacteria or endostatin alone had little effect on tumor growth. In contrast, combined bacteriolytic and anti-angiogenic therapy proved very effective at reducing tumor growth, and was associated with marked tumor necrosis. These data indicate that combined therapy using tumor-targeting bacteria that can fight tumors using their unique metabolic features from poorly perfused tumor areas, (which are not accessible to systemically administered agents), along with inhibition of angiogenisis to kill residual tumor cells significantly increases the chance of tumor eradication. Also, it is less likely that resistance to such combination therapy will develop. Below, we discuss four different approaches for using modified bacteria as anti-cancer therapeutics-bactofection, DNA vaccination, alternative gene therapy (AGT) and transkingdom RNA interference (RNAi)-with a specific focus on angiogenesis suppression (Figure 1 ).
BACTOFECTION
The use of bacteria as a vector for the delivery of therapeutic genes to target cells is known as bactofection, and several studies have used this approach to deliver genes encoding anti-angiogenic molecules to tumor cells in vivo. A study was performed using S. choleraesuis strain bearing eukaryotic expression plasmid encoding endostatin. 22 The expression of endostatin was targeted exclusively to tumor tissues colonized by bacteria and significant inhibition of tumor growth (40-70%) with decreased intratumoral microvessel density and reduced expression of vascular endothelial growth factor (VEGF) was observed. Bactofection using auxotrophic Salmonellae as vectors has also been effectively used for therapy of experimental tumor models using expression plasmids carrying various cytokine genes, such as interleukin-12 (IL-12) and GM-CSF, 23 IL-4 and IL-18 (see ref. 24) or other molecules having role in angiogenesis such as Flt3 ligand. 25 Further, a dual tumoricidal and anti-angiogenic effect of S. choleraesuis carrying an expression plasmid containing the thrombospondin-1 gene under control of eukaryotic promoter was observed in a murine model of malignant melanoma. 26 However, on the basis of the small number of studies using bactofection for cancer treatment, it seems that this approach is more suited to targeting other cells and tissues such as the colonic mucosa 27 and the lungs. 28 A potential limitation of bactofection for cancer therapy is the fact that the effector molecule will likely be expressed exclusively in cells infected by bacteria, leaving a potentially large population of tumor cells untreated. However, if the product of the transgene is secreted outside the target cell, it may still have a therapeutic effect on noninfected tumor cells. Bacterial strains, delivery routes, genes, tumors and mouse strains used in studies using bactofection are summarized in Table 1 .
DNA VACCINATION
It is known that bactofection of plasmids encoding a tumor-expressed antigens can lead to induction of humoral and cellular immune response in the host thereby providing protective defense against tumors. 29 This approach, termed DNA vaccination, has been successfully implemented for anti-angiogenic therapy. Oral anti-angiogenic bacterial vaccines directed against VEGFR-2 have proved efficicious in animal models of malignant melanoma, colorectal carcinoma and lung cancer, 30 as well as non-cancer diseases like stromal keratitis 31 and atherosclerosis. 32, 33 Furthermore, Salmonella-mediated vaccination against murine VEGFR-2 has been successfully combined with classical gene therapy for the treatment of malignant melanoma. 34 In this study, oral administration of a vaccine strain combined with direct intratumoral injection of plasmid vector encoding the chemokine IP-10 (CXCL10) resulted in a significant synergistic anti-tumor effect. Similar suppression of angiogenesis was observed with an oral bacterial vaccine against IL-18 alone and combination with Fos-related antigen 1. 35 Bacterial vaccines directed against the apoptosis inhibitor survivin 36 and the transforming growth factor-b1 co-receptor endoglin 37 also proved effective for inhibition of tumor angiogenesis. Taken together, these findings underscore the key role of angiogenesis in cancer as well as other diseases and, at the same time, highlight the complexity of this essential process. Most DNA vaccination studies for anti-cancer therapy use attenuated strains of Salmonella whose suitability has been demonstrated in numerous investigations. Other bacterial species, however, have also been used such as Pseudomonas aeruginosa. 38 For a comprehensive review of the bacterial strains used for DNA vaccination please see the article by Xiang et al. 39 Most of the above mentioned vaccines induce a protective CD8+ T-cell-mediated immune response that most likely reflects a breakdown of peripheral immunological tolerance to self-antigens. The precise molecular mechanism that regulates this phenomenon, however, remains obscure. The need for further research and deeper understanding of these phenomena is highlighted by the fact that similar vector strains are currently used for bactofection-based approaches and for DNA vaccination. In bactofection and bacterial gene-therapy approaches, the immune activation may be seen as an undesired side effect, whereas in DNA-vaccination, the immunogenic properties of the carrier-bacteria are a pivotal component of the therapeutic effect.
One of the main advantages of bacterial DNA vaccination as a cancer treatment strategy is the potential for oral application of Bacteria in cancer gene therapy R Gardlik et al therapeutic bacterial strains, which was proven to be effective in animal studies. Current research is focused on the development of clinically relevant oral bacterial vaccines. However, significant knowledge gaps still exist and the mechanism of action for oral DNA vaccines has not been fully elucidated yet. Recent animal experiments investigating angiogenesis-related anti-tumor DNA vaccination studies are summarized in Table 2 .
ALTERNATIVE GENE THERAPY
Another means of using bacteria for gene therapy is the so-called AGT approach, which is also known as bacterial protein delivery. 40 It is based on transfer of bacterially expressed therapeutic proteins to the host organism using genetically modified (transformed) bacteria. Unlike bactofection-and DNA vaccination-based methods, the persistence of bacteria in target tissue may be desired in bacterial protein Bacteria in cancer gene therapy R Gardlik et al delivery. Persisting bacteria produce the therapeutic polypeptide in situ, thus ideally providing a local distribution of drug without increasing its systemic levels. As with bactofection, AGT is mostly used for treatment of tumors and uses primarily oncolytic and tumor-colonizing bacterial strains of Clostridia, Bifidobacteria or Salmonellae. 2, 4 Both Clostridia and Bifidobacteria have been successfully used for 'enzyme-prodrug' therapy. 41 Owing to their obligate anaerobic nature, ability to form spores and ease of transformation, Clostridia are especially suited to AGT for tumors. 42, 43 Further, their ability to colonize tumors in vivo can be enhanced by deletion of genes associated with basal oxygen tolerance, such as that encoding superoxide dismutase. 44 The main advantage of Bifidobacteria, on the other hand, is that they are non-pathogenic. Li et al. 45 successfully used Bifidobacterium adolescentis as a vector for the expression of endostatin within tumors. These authors showed that a strong inhibition of angiogenesis was able to significantly inhibit local tumor growth. In another study, Bifidobacterium longum was shown to efficiently deliver the anti-angiogenic protein endostatin to murine liver tumors and induce anti-tumor activity. 46, 47 Furthermore, the anti-tumor effect was enhanced by co-administration of the same bacterial strain expressing tumor necrosis factor-related apoptosis inducing ligand. 48 These findings emphasize the need for combination therapy, in which multiple anti-tumor pathways are inhibited. A key aspect of the studies investigating in vivo AGT is the ability to specifically regulate bacterial expression of the therapeutic protein.
Precise temporal and spatial control is necessary to maximize the therapeutic effect and minimize the any potential adverse effects. One of the key tools in this area is the use of inducible promoters that are activated only in the presence of a specific exogenously administered compound (for example, isopropyl thiogalactoside and arabinose). Exogenous regulation of therapeutic gene expression can also be further improved by the use of bacteria carrying inducible suicide genes. An important study by Loessner et al. has demonstrated the ability to regulate the expression of therapeutic genes from plasmids in vivo. 49 In this study, intravenously applied S. typhimurium carrying a plasmid containing green fluorescent protein (GFP) gene under control of arabinose (pBAD) promoter were able to selectively colonize tumors, but only expressed green fluorescent protein after administration of L-arabinose. Bacteria-mediated transfer of therapeutic proteins to tumors using an L-arabinose expression induction system has also been reported for E. coli Nissle 1917, a probiotic bacterial strain that can colonize humans. 50 The results of this study significantly advance the exploitation of this gut-trophic strain and provide a good example of the therapeutic potential of AGT. However, despite the excellent safety profile of E. coli Nissle 1917, it is quite challenging to genetically engineer this bacterial strain mainly because of the presence of several inherent plasmids. In addition, the overwhelming majority of literature about E. coli Nissle 1917 studies discusses its beneficial use for gastrointestinal indications. Thus, more studies are needed to uncover its potential for anti-tumor therapy. However, it seems that other live bacterial vectors might be more suitable for systemic intravenous therapy of cancer.
Another approach being investigated to improve regulated gene expression as well as the targeting of bacteria to the hypoxic (that is, poorly vascularized) regions of tumors is the use of hypoxia responsive promoters in tumor-colonizing Salmonellae. 51, 52 A subset of promoters preferentially activated inside tumors has been identified recently, suggesting that there are additional regulatory mechanisms beside those hypoxia-related. 53 This is particularly interesting in light of recent findings regarding the ability of tumor-targeting bacteria to colonize both the necrotic and well-perfused areas of tumors. 6, 54 These results further enhance the potential of using bacteria for anti-tumor gene therapy, by providing a wider variety of promoters capable of tumor targeting and regulated gene expression. Also, bacteria have an advantage over viruses when used for cancer gene therapy as the therapy can be readily terminated using antibiotics. Moreover, bacteria do not integrate genetic material into host genome, significantly reducing the risk of treatment-induced mutagenesis and tumorigenesis. In situ production of cytokines by bacteria represents a costeffective and safe alternative mainly to systemic administration, which can be associated with unwanted side effects. However, in recent study using Listeria monocytogenes as a vehicle for tumor specific gene and protein delivery, bactofection proved to be more efficient than AGT. 55 An important study was performed recently by Loeffler et al. 56 that engineered attenuated S. typhimurium to improve their oncolytic activity by stably incorporating a gene encoding LIGHT, a tumor necrosis factor-family cytokine known to promote tumor rejection. LIGHT has various roles in immune response mechanisms including stimulation of B and T cell as well as natural killer cell migration. More importantly, LIGHT may have direct anti-angiogenic effects through activation of chemokine CXCL9 and CXCL10 receptors known for triggering the processes leading to angiogenesis inhibition. In a follow-up study, the same authors demonstrated an anti-tumor effect of IL-18 producing Salmonellae. 57 Besides its well-known effect on the immune system, IL-18 also acts as a suppressor of angiogenesis by direct inhibition of fibroblast growth factor 2-induced endothelial cell proliferation and, thus, inhibits various pathways involved in tumor pathogenesis. Taken together, these studies provide evidence that intravenously administered, non-virulent genetically modified bacteria, can be efficiently exploited as vehicles for local generation Bacteria in cancer gene therapy R Gardlik et al of anti-angiogenic agents in tumors. The same authors recently published two additional experimental studies using immunocompetent mice models of cancer, in which they demonstrated in vivo the anti-tumor effect of attenuated S. typhimurium producing the chemokine CCL21, and proapoptotic cytokine Fas ligand suggesting the molecules also possess angiostatic properties. 58, 59 Interestingly, a pronounced anti-tumor effect of IL-2-producing S. typhimurium was also recently shown in a mouse model of melanoma. 60 Moreover, this effect was clearly correlated with decreased tumor angiogenesis. In fact, previously unknown anti-angiogenic effects have recently been discovered for a variety of molecules involved in the immune response and cellular apoptosis mainly due to extensive ongoing research in the field of cancer therapy. Bacteria in gene therapy, differences between bactofection and AGT, advantages and disadvantages, as well as specific application of both approaches are discussed in detail in our review article. 40 A detailed summary of experimental studies using AGT is provided in Table 3 . In spite of great success in a preclinical setting, the application of bacteria for human tumor therapy has not been particularly efficacious, although this approach was well tolerated in most studies. [61] [62] [63] In light of above-mentioned findings, however, we would suggest that angiogenesis would be a meaningful target for further experimental and clinical studies of bacteria-mediated anti-cancer therapy, particularly if used in conjunction with oncolytic strains of bacteria.
TRANSKINGDOM RNAi
A promising new approach for bacteria-mediated anti-cancer therapy is the combination of two distinct methodologies: bacteriotherapy and RNAi. Bacteria that were engineered to produce and deliver short interfering RNA (siRNA) represent a novel tool for the efficient induction of RNAi in host cells. 64 This concept was pursued independently by Zhao et al. 65 and Xiang et al. 17 Zhao et al. showed that siRNAs produced by invasive E. coli strain could induce RNAi in mammalian cell cultures. The first in vivo demonstration of transkingdom RNAi was provided by Xiang et al. who showed that invasive E. coli capable of producing b-catenin short-hairpin RNA could induce RNAi in colonic epithelial cells and colonic tumors xenografted into nude mice. This approach is termed transkingdom RNAi, as this study provided the first evidence of transfer of RNAi effector molecules between bacteria and mammals in vivo. In another study, attenuated S. typhimurium were also successfully tested as a vector for in vivo transfer of MDR1 siRNA to tumors. 66 Combined oncolytic and siRNA therapy using systematically administered attenuated S. typhimurium expressing siRNA against tumor transcription factor STAT3 has also been evaluated. 67 Both of these studies demonstrated higher efficiency for combined therapy compared with treatment with nonRNAi-inducing bacteria. In addition to being used to produce and deliver silencing short-hairpin RNA, bacteria can also been exploited to deliver eukaryotic short-hairpin RNA-expression plasmids to mammalian tumor cells. 17 Oral administration of S. typhimurium bearing an short-hairpin RNA-expression plasmid against the antiapoptotic protein bcl-2 led to a marked delay in tumor growth, and prolonged survival in a murine melanoma model. 68 To date, however, transkingdom RNAi has not been used to directly target angiogenesis, although some of the targets mentioned above (b-catenin, STAT3 and bcl-2) are known to augment angiogenesis through their effects on the expression of various proangiogenic factors. [69] [70] [71] Anti-tumor effects of knocking down these targets may, in part, be related to suppression of blood vessel formation. However, a number of studies using 'non-bacterial' application of siRNA against VEGF, 72, 73 HIF-1a 74 and other angiogenesis-related molecules 75 indicates that inhibition of endothelial cell proliferation and new blood vessel formation are a viable target for RNAi-based treatment of cancer, as well as other diseases. 76 Although transkingdom RNAi clearly provides a new avenue to explore, further studies will be required to uncover all its potential applications. Table 4 provides a brief summary of studies using transkingdom RNAi in tumor therapy.
CONCLUSION
Inhibition of angiogenesis is of great importance from experimental, pathophysiological and especially clinical point of view. However, further research is needed to fully delineate the most effective way to target angiogenesis for cancer treatment. The application of new approaches using bacteria for the transfer of therapeutic genes or the Loeffler et al. 53 Loeffler et al. 54 Loeffler Bacteria in cancer gene therapy R Gardlik et al production of therapeutic protein or small RNAs has the potential to significantly advance cancer gene therapy. Recent studies indicate that treatments targeting a single molecule/pathway, even if it has pleiotropic effects, are unlikely to be able to completely eradicate tumors; however, if the natural anti-tumor activity inherent to some anaerobic bacteria strains can be successfully combined with their ability to deliver agents targeting tumor angiogenesis, apoptosis or the immune system, this will represent a significant step toward reaching this important goal. Interconnection of reasonable and important objectives (targeting angiogenesis) with novel interesting strategies (bactofection, AGT and transkingdom RNAi) can open new research area and bring success in solving the most serious biomedical problems. Future directions, which may move the field forward include improved spatial and temporal regulation of bacterial therapy, better specificity (tumor and gene targeting) and the development of other potential approaches (for example, micro RNA based). All of the above mentioned improvements can be combined with bacterial delivery systems to achieve synergistic anti-cancer effects and represent an excellent avenue for combination therapy. Nevertheless, safety issues and public attitude will have a great impact on the adoption of bacteria-mediated anti-cancer therapy for clinical use. Therefore, these aspects will need to be carefully addressed to move the bacteriabased therapies from the bench to the bedside. Recently, transkingdom RNAi targeting b-catenin has received clearance from US Food and Drug Administration to initiate clinical trials for treating patients with familial adenomatous polyposis, 17 suggesting the feasibility and promise of bacteria-based therapy for cancer.
